Phase I trial to assess safety and pharmacokinetics of Gefitinib plus S-1 combination therapy in patients with advanced adenocarcinoma lung.
Phase of Trial: Phase I
Latest Information Update: 09 May 2017
At a glance
- Drugs Gefitinib (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 24 Dec 2008 New trial record.